drugset

drugset / Trial / NCT07179055

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT07179055 ↗

Phase 2 Recruiting 160 enrolled Vanda Pharmaceuticals

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Timeline

Start: 2025-10
Primary completion: 2026-09
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VSJ-110	Unknown	—	Other

Indications